Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Oncology
Oncology · The big question

Combining Two Therapies Improves Survival in Severe Liver Cancer

Microwave Ablation with or without TACE for Unresectable Large Hepatocellular Carcinoma: Impact of Tumor Burden Score on Efficacy.

PubMed2 min readAI-assisted summary
Editorial illustration for Microwave Ablation with or without TACE for Unresectable Large Hepatocellular Carcinoma: Impact of Tumor Burden Score on Efficacy.
Editorial illustration

Summary

Liver cancer can be notoriously difficult to treat, especially when tumors become too large to be safely removed with surgery. For these challenging cases, doctors often rely on alternative methods to destroy the cancer cells. One common technique is microwave ablation, which uses targeted heat to destroy the tumors. Another is transarterial chemoembolization, or TACE, which cuts off the blood supply to the tumor while delivering localized chemotherapy. While some patients receive only the heat treatment, medical professionals have debated whether a sequential combination of both therapies might yield better results.

To find out, researchers compared the outcomes of 103 patients who received only the heat treatment against 103 matched patients who received TACE followed by microwave ablation. Overall, the sequential combination therapy proved much more effective at keeping the cancer from progressing. The combined approach was also significantly better at preventing the tumors from spreading to other distant parts of the liver.

Interestingly, the research revealed that the most effective treatment depends heavily on the extent of the disease, which doctors measure using a tool called the Tumor Burden Score. For patients with a lower score of less than 5.7, the single heat treatment worked just as well as the combination. However, for those with a high score of 7.5 or greater, combining both treatments significantly improved overall survival rates, making it the clear priority for severe cases.

Why it matters.

This research highlights the growing importance of tailored treatment plans in oncology. By calculating a tumor score, doctors can avoid a rigid, standardized approach to liver cancer. Sparing patients with less extensive disease from a second procedure can save them from additional physical strain and unnecessary medical costs. Conversely, identifying exactly which patients need the aggressive two-step therapy ensures that those with severe, inoperable liver tumors get the treatment most likely to extend their lives.

It is important to note that these findings come from a retrospective look at past patient records from a single medical institution. Before this customized approach becomes a universal standard, the results will need to be confirmed by broader studies across multiple hospitals. Even so, the study provides a practical, evidence-based guide to help doctors make smarter, more individualized choices for their patients.

From the source

The story in numbers.

Total patients in the retrospective cohort
294
Median follow-up duration
67.3 months
Tumor Burden Score (TBS) threshold prioritizing combined treatment
7.5
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Oncology

Targeted Drug Spares Lymphoma Patients from Stem Cell Transplants

Mantle cell lymphoma is a challenging type of blood cancer. For years, the standard treatment for younger, relatively fit patients has been a heavy dose of chemotherapy followed by an autologous stem cell transplant. This transplant process involves collecting a patient's own healthy stem cells, delivering high-dose chemotherapy to wipe out the cancer, and then returning the healthy cells to help the body recover. It is an intense procedure that can be incredibly hard on the body. A recent major clinical trial followed 870 patients across Europe and Israel for over four years to see if adding a targeted daily pill called ibrutinib could improve outcomes. Researchers split the patients into three groups to test different combinations of standard chemotherapy, ibrutinib, and stem cell transplants. They found that adding ibrutinib significantly boosted both how long patients lived overall and how long they lived without their cancer returning or worsening. The most welcome discovery was that the grueling stem cell transplant may no longer be necessary. The group that received chemotherapy and ibrutinib but skipped the transplant did just as well as the group that received all three. Adding the transplant to the ibrutinib regimen provided no extra survival benefit but significantly increased the risk of severe side effects, like dangerous drops in healthy blood cells. It is worth noting that this study only looked at untreated patients aged 18 to 65, so the findings might not apply to older or less fit individuals.

PubMed2 min read
Oncology

Colorectal Cancer Prepares to Spread Earlier Than We Thought

For anyone diagnosed with cancer, the most dangerous moment is when the disease begins to spread to new areas of the body, a process known as metastasis. Scientists have long wondered exactly when and how a localized tumor gains the ability to travel. In a new study looking at colorectal cancer, researchers made a surprising discovery. They found that tumors actually develop the necessary tools to spread much earlier than previously believed. By studying patient samples and miniature lab-grown tumors called organoids, the research team looked at how tumor cells behave at a microscopic level. They discovered that many early-stage tumors adopt a highly flexible condition called an oncofetal state. Normally, this shapeshifting ability is only seen in advanced, late-stage cancers. But the researchers found that these flexible cancer cells were already gathering at the edges of early tumors. There, they mingle with normal connective tissue cells known as fibroblasts, which actively encourage the cancer cells to become even more adaptable and ready to move. However, simply having these flexible cells is not enough to guarantee the cancer will spread, since not all early-stage tumors actually go on to metastasize. The researchers investigated what pushes the tumor over the edge. They ruled out new genetic mutations as the trigger. Instead, their findings suggest that a cancer cell's ability to hide from the immune system might be the final key to unlocking its deadly spread.

Nature Genetics2 min read
Oncology

New nanoparticle tech breaks down tumor shields to boost immunity

Tumors have a sneaky way of hiding from the body's immune system. They wrap themselves in a dense, sugary protective coating known as the glycocalyx. This shield is packed with mucins, which are thick proteins that physically block immune cells and modern cancer treatments from reaching the target. While scientists have discovered a bacterial enzyme called StcE that can chew through this sticky barrier, using it as a drug has been difficult. Injecting the free enzyme directly into the body causes unwanted toxic side effects and triggers severe immune reactions. To solve this problem, researchers engineered a clever delivery system using cell membrane fusion nanovesicles, which are essentially microscopic bubbles made from natural cell materials. They equipped these tiny delivery vehicles with both the barrier-breaking StcE enzyme and specialized targeting molecules called CD47 nanobodies. These nanobodies act like a homing device that seeks out cancer cells. By using this biomimetic delivery platform, the enzyme successfully digests the protective sugary shield precisely at the tumor site, avoiding the widespread toxicity and safety issues of the free enzyme. With the barrier cleared away, the immune system gets a much clearer shot at the tumor. The researchers found that removing the mucin shield allowed the nanobodies to bind tightly to the cancer cells, sounding the alarm for the body's natural defenses. The treatment successfully suppressed tumor growth and stopped the cancer from spreading by radically remodeling the environment around the tumor, bringing in a flood of protective immune cells.

PubMed2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗
Combining Two Therapies Improves Survival in Severe Liver Cancer — Daily Strand